Warning this in not the USBIOVEST from Seeking Alpha. I do not know how you have my screen name but it's been reported to Yahoo!
Athersys is a solid company in my opinion and those opinions can be read on Seeking Alpha under U.S. Biotech Investor.
Besides a technical pull back down to $1.80 being needed here are some concersn of mine.
Competition and patent issues. The MPC cell and MAPCs are similar and Mesoblast owns the MPCs and they are not the same as the MSC cells that MAPCs are compared against.
Can MAPCs really ever be classified as a drug? Real problems and costly clinical trial to get that rating IMO.
The AMI even if it ever partners Athersys must hand the upfront money over to their old partner and I think Mesoblast owns them now. Seriously ATHX has major issues.
If the ulcerative colitis trial was going well it would be finished. Even double blinded doctors who treat multiple patients would see half improve faster than normal. Looks to me like they are not seeing this?
Cash is still a problem and on any real gain they will raise capital again. I would not be surprised to see this company go under. That's right GO COMPLETELY UNDER !!!
You can lose all your money on an anti-inflammatory pipe dream. This is just scratching the surface and I will post my real concerns later. Ponder this please before you get suckered by a management team that is all to comfortable with delays. Read and see the pastern.
All this is just my concerned opinion and not posted as fact just posted to give both sides and some don't like it!!!!
No, it's not ACAD because it's going higher than ACAD. GALE is also not CLDX because GALE will hold over $40 better than CLDX once getting there. As to the original comment about selling, seriously are you a rookie? The fact is big share holders self included sell some to buy back cheaper. We always have a growing core ad profits used from trading buy more shares. If at some point the share price gets away then the core position is still enjoyed and it's not rocket science.
Sentiment: Strong Buy
This is apposed to the shorts who have a thread that says $2 is more likely than $6. One title is true and it favors the longs while burning fools who short stocks like GALE. On a second not, The Street articles are worthless. Dead cat bounce? Yeah, OK. Lmfao. They also said that about CYTR. GALE is going higher end of story and the reality!!!
The just did one and have the Aspire Capital deal to fall back on so you are either sturring up trouble or have done absolutely no due diligence. I imagine it's the first scenario.
World’s first stem cell drug approved in Canada | InPharm
World’s first stem cell drug approved in Canada | InPharm | The Pharmaceutical Industry May 21, 2012 4:14 PM
Canada has approved the world’s first stem cell drug, marking an historic day for the burgeoning therapy.
Osiris' Prochymal is now approved in Canada in children with graft versus host disease (GvHD), a potentially deadly complication from a bone marrow transplant, when newly implanted cells attack the patient’s body.
Prochymal is made up of bone marrow stem cells derived from an adult donor and is designed to control inflammation, promote tissue regeneration and prevent scar formation – GvHD affects around 3,500 to 4,000 worldwide.
*** MAPCs are better and the trials are better... the MSCs were called a drug as will MultiStem be able to be classified that way.
Sentiment: Strong Buy
nkl0145, Athersys did pick area's it thought MultiStem would do very well in. That said they will have some ups and downs all companies do. My opinion is the UC trial will advance to phase III after they spend some thought on how to proceed and use the data best to set up a Crohn's Disease trial for the phase III trial. For stroke expect a move to phase III and some deals with Japan. Those are my thoughts only.
Some area's that people have not even thought about will also develop as Athersys grows and becomes better funded. Athersys currently limits its scope due to funding.... also IMO
Sentiment: Strong Buy
It's been proven that the phenotype of the MAPCs differs from the MSC cell line. And even Mesoblast knows it. If a dispute existed it would be likely Athersys who made the claims. United States patent 7,659,118 that covers non-embryonic multipotent stem cells, their isolation and expansion, and related pharmaceutical compositions.
European patent EP1218489B1 that covers non - embryonic pluripotent stem cells, their isolation, expansion, and usage.
Part of the patent process in Europe is an opposition period. During this period no complaints arose.
Athersys patents will become more important as the technology expands and becomes main stream. That's likely why Athersys spent an increased $193,000 on patent legal fee's in Q2 2013.
Athersys is currently patent protected until the year 2028.
What most don't yet grasp is the fact MultiStem can not completely fail as a treatment.... it works already.
What application does it work with? Orthopedic and other biologic implants!
It's also a fairly safe bet it's going to work with GvHD if you take a look at the technology and what it does.
This company is not a one trick pony even on a fail in one area... that makes this a truly unique opportunity.
MultiStem is a robust stem cell technology platform - it does not have to work on every indication to generate huge returns for Athersys.
OSIR sold you guys out to Mesoblast plain and simple
The title of this post refers to the OSIR stock move up to that price on similar stem cells, yet, inferior stem cells in terms of effect on the same applications. When someone has a stroke do you think they will want number two or the number one treatment? The point is if OSIR went to $27.40, ATHX will go much higher.
OSIR sold its investors out to Mesoblast on the cheap and that also is good for Athersys. ATHX the only solid American play left in the adult bone marrow sect. This company is no joke and those who use even a moderate amount of due diligence should see ATHX as the best play in the regenerative medicine sect.
The market is down ATHX is up... the sell off was from profit taking as ATHX was up to $2.50 pre-market. Even smart longs took some and bought back more shares. It's a great day the floats getting smaller and some real news will launch ATHX and we have plenty of that coming. Not just the UC and IS trial data either.
I tend to be conservative, however, agree with the values you gave. That's why I said $5 minimum and did not give the high end. This run really is in its infancy even though it's been a good run from under $2. All the bid runners start out the same way. Few have the staying power that GALE has in Abstral to start the higher run and NeuVax to continue it on like a CLDX type run. None of this is hype, yet, some will think that of these comments.